NCI-2024-06636

A Phase 1b/2 trial of Lamivudine in the Treatment of Relapsed/Refractory Solid Tumors Progression on Anti-PD-(L)1 blockade

This is a Phase 1b/2 clinical trial testing a drug called Lamivudine to treat patients with relapsed or refractory solid tumors (cancers that have come back or do not respond to treatment) who have not improved after using Anti-PD-(L)1 therapy. PD-(L)1 is an immune checkpoint protein that cancers can use to hide from the body’s immune system. Anti-PD-(L)1 drugs block this process, allowing the immune system to attack the cancer. When the cancer continues to grow despite this treatment, it is called "progression on anti-PD-(L)1 blockade."

Relapsed or Refractory: Cancer that does not respond to treatment is called refractory and can be known as resistant cancer. The cancer may be resistant to therapy at the beginning of treatment or during treatment.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06494579

Clinical Trial Site: Sinai

To see all available clinical trials click here.